Search Mailing List Archives

Limit search to: Subject & Body Subject Author
Sort by: Reverse Sort
Limit to: All This Week Last Week This Month Last Month
Select Date Range     through    

[bioontology-support] NCBO annotator web service

Trish Whetzel whetzel at
Tue Aug 17 10:32:56 PDT 2010

Sure, the attachment did not come through. Can you re-send?


On Aug 17, 2010, at 10:21 AM, Lorena Carlo wrote:

> Hi Trish,
> I am getting the following error from the web service:
> 502
> <html><head>
> <title>502 Proxy Error</title>
> </head><body>
> <h1>Proxy Error</h1>
> <p>The proxy server received an invalid
> response from an upstream server.<br />
> The proxy server could not handle the request <em><a href="/obs/ 
> annotator/submit
> /mlc2200 at">POST /obs/annotator/submit/mlc2200 at 
> </a><
> /em>.<p>
> Reason: <strong>Error reading from remote server</strong></p></p>
> <hr>
> <address>Apache/2.2.13 (Red Hat) Server at Port  
> 80</address
> >
> </body></html>
> I am attaching the file I am using. Can you help me checking this.  
> Thanks.
> Best,
> Lorena
> Trish Whetzel wrote:
>> We do not yet have an absolute requirement for the email address.  
>> However, our funders are very interested to know who and how people  
>> are using the Web services that we provide.
>> Thanks,
>> Trish
>> On Aug 10, 2010, at 1:08 AM, Lorena Carlo wrote:
>>> Hi Trish,
>>> Ok, no problem I will change it, thanks. I would like to ask why  
>>> is the email address required?. Thanks.
>>> Best regards,
>>> Lorena
>>> Trish Whetzel wrote:
>>>> Hi Lorena and Ying,
>>>> Can you replace the following line in the Python code to access  
>>>> the Annotator:
>>>> # Submit job
>>>> submitUrl = annotatorUrl + '/submit'
>>>> with
>>>> # Submit job
>>>> submitUrl = annotatorUrl + '/submit/example at'
>>>> and include your email address?
>>>> Thanks,
>>>> Trish
>>>> On Aug 4, 2010, at 12:20 PM, Trish Whetzel wrote:
>>>>> I also wanted to mention that we have a NCBO Annotator Google  
>>>>> group (  
>>>>> intended to be a space where Annotator users can discuss their  
>>>>> use cases for the Annotator and choice of ontologies,  
>>>>> parameters, etc.
>>>>> Trish
>>>>> On Aug 4, 2010, at 9:48 AM, Lorena Carlo wrote:
>>>>>> Dear Trish,
>>>>>> Thanks for your email. I am copying this email to Ying, she is  
>>>>>> a student here at Columbia and will be using the annotator  
>>>>>> service with python too. Thanks.
>>>>>> Best regards,
>>>>>> Lorena
>>>>>> Trish Whetzel wrote:
>>>>>>> I'm not aware of anyone using the Annotator Web service in  
>>>>>>> Python, however attached is an Annotator client example in  
>>>>>>> Python.
>>>>>>> Trish
>>>>>>> ------------------------------------------------------------------------
>>>>>>> On Aug 3, 2010, at 1:48 PM, Lorena Carlo wrote:
>>>>>>>> Hi Trish, Thanks for your email. I would like to know if  
>>>>>>>> there is people in the community using python and the  
>>>>>>>> annotator web service?. If so can you redirect me to the  
>>>>>>>> resources that will help me to use this web service in  
>>>>>>>> python?. Thanks!. Best regards, Lorena Trish Whetzel wrote:
>>>>>>>>> Hi Lorena, Let me know if you have any questions about  
>>>>>>>>> accessing the Annotator via the REST Web service. Also, if  
>>>>>>>>> you are able to share information on your use case for the  
>>>>>>>>> Annotator with our Google group that would be wonderful: 
>>>>>>>>> . Best regards, Trish On Aug 3, 2010, at 12:45 PM, Clement  
>>>>>>>>> Marie Jonquet wrote:
>>>>>>>>>> Dear Lorena, There is unfortunately no SOAP web services  
>>>>>>>>>> for the Annotator. This is only deployed as a REST service  
>>>>>>>>>> and HTML, Java, Perl and Ruby on rails client are  
>>>>>>>>>> available: 
>>>>>>>>>>  Hope you will still use it. We will let you know if this  
>>>>>>>>>> situation change in the future. Please follow up  
>>>>>>>>>> conversation with Trish Whetzel (CC), as I will not be at  
>>>>>>>>>> Stanford any time soon. Clement  
>>>>>>>>>> -------------------------------------------------------------------------- ------------------------- Dr 
>>>>>>>>>> . Clement JONQUET  -  PhD in Informatics  -  Postdoctoral  
>>>>>>>>>> Research Fellow jonquet at <mailto:jonquet at 
>>>>>>>>>> > < 
>>>>>>>>>> > Stanford Center for Biomedical Informatics Research  
>>>>>>>>>> (BMIR) Medical School Office Building, Room X-215 251  
>>>>>>>>>> Campus Drive Stanford, CA 94305-5479 USA Tel:        +1 650  
>>>>>>>>>> 724-0388 Fax:       +1  650 725-7944 Skype:  clementpro 
>>>>>>>>>> -------------------------------------------------------------------------- ------------------------- -----Original 
>>>>>>>>>>  Message----- From: Lorena Carlo [mailto:lorena.carlo at 
>>>>>>>>>> ] Sent: Tuesday, August 03, 2010 11:38 AM To: jonquet at 
>>>>>>>>>>  <mailto:jonquet at> Subject: NCBO annotator web  
>>>>>>>>>> service Dear Clement Jonquet, I am interested in using the  
>>>>>>>>>> NCBO annotator  web service in an python application. I  
>>>>>>>>>> don't find the web service wsdl. Can you send me the wsdl  
>>>>>>>>>> URL?.  Thanks. Best regards, Lorena Carlo PhD student in  
>>>>>>>>>> Biomedical Informatics Columbia University
>>>>>>>>> Trish Whetzel, PhD Outreach Coordinator The National Center  
>>>>>>>>> for Biomedical Ontology Ph: 650-721-2378  
>>>>>>>>> whetzel at <mailto:whetzel at>
> SGOT/SGPT no greater than 3 times ULN.
> Fertile patients must use 2 methods of effective contraception.
> No disease limited to the skin regardless of how wide-spread.
> Progressive disease after chemotherapy, radiotherapy, surgery or  
> immuno-therapy, and be no longer responding to such therapy, or have  
> refused such therapy.
> normal weight-for-height weight 50-80 kg.
> Must weigh at least 50 kg.
> Systemic corticosteroid use for acute problems, as medically  
> indicated.
> At least 1 week since discontinuation of prior pulmonary  
> hypertension medication, except anticoagulants.
> At least 2 weeks since prior radiotherapy (before vaccination).
> Lymphoblastic lymphoma.
> At least 2 weeks since prior phototherapy (ultraviolet B [UVB] or  
> PUVA light therapy).
> After 9 or 12 months of IFN-A, no cytogenetic response occurred  
> (100% Ph+), regardless of pretreatment clinical features.
> At least 4 weeks since prior PC-SPES.
> At least 6 months since prior oral retinoids.
> WBC at least 20,000/mm^3 after at least 3 months of interferon  
> therapy.
> Diffusion capacity at least 50%.
> At least 1 measurable lesion outside a previously irradiated area or  
> an area treated with physical devices (e.g., cryotherapy, laser, or  
> thermoablation).
> Resistant or recurrent disease after combination chemotherapy with  
> at least one standard regimen OR.
> Weigh at least 50 kg (110 lbs) and are within 30 percent of their  
> ideal body weight.
> LVEF greater than 40% by echocardiography or MUGA.
> Transaminases no greater than 2.5 times upper limit of normal (ULN).
> Platelets > 100,000 / ml.
>> 6 months of prior AZT. Required for open-label study patients:.
> HIV RNA PCR (Amplicor) > 10,000 copies/ml.
> Prior greater than or equal to grade 3 rash or any desquamating  
> (blistering) rash while taking thalidomide.
> No potassium less than 3.0 or greater than 5.5 mEq/L that can not be  
> corrected OR.
> Renal: Creatinine less than 1.5 mg/dL OR Creatinine clearance  
> greater than 60 mL/min.
> Age less than 20 or greater than 69 years.
> No more than 1 prior biologic therapy regimen.
> Under 55 at time of umbilical cord blood transplantation.
> Intolerance to lithium or lamotrigine.
> Histologically confirmed atypical endometrial hyperplasia with  
> recommended treatment with either:.
> Patients who have received prior radiotherapy to the marker  
> lesion(s) must have disease progression in that lesion since  
> treatment.
> Hepatitis B antigen positive at study entry.
> Family residence in the greater Boston area.
> Diagnosis of osteoarthritis of the knee (fulfilling ACR criteria)  
> for at least 6 months duration.
> Pfizer must be notified if the patient is receiving ganciclovir  
> (DHPG) at entry.
> No prior AD 32 for bladder cancer.
> Hematologic, renal, or hepatic insufficiency.
> Histologically or cytologically confirmed colorectal adenocarcinoma.
> Active tuberculosis (TB).
> Requirement for blood transfusions more than once a month.
> No uncontrolled systemic nonmalignant disease or infection.
> No active ongoing infection.
> Has ever taken SQV or NFV.
> Autoimmune disorder.
> Retreatment with taxane/platinum after initial combination is  
> considered only 1 regimen.
> Primary or previously treated disease.
> Diagnosis of ulcerative colitis of at least 6 months duration.
> Subject with currently diagnosed life-threatening asthma.
> Adequate psychosocial support required.
> At least 6 months since myocardial infarction, congestive heart  
> failure, symptomatic angina, life threatening arrhythmia, or  
> hypertension.
> Medical conditions contraindicating use of fluoxetine.
> More than 21 days since prior chemotherapy.
> Have an AIDS-defining illness.
> Patients who have had an AIDS-defining illness that was cured may  
> still be eligible.
> No clinically significant immunodeficiency.
> Psychiatric disease.
> Concurrent aspirin (325 mg/day) for cardioprotection allowed.
> Hepatitis B (HBsAg reactive).
> No concurrent medical condition that is likely to interfere with  
> study.
> Current random fine needle breast aspiration (FNA) evidence of 1 of  
> the following:.
> Antacids for 4 hours before and 4 hours after itraconazole.
> Islet cell.
> No prior gemcitabine and/or LY231514.
> At least 3 weeks since prior interstitial brachytherapy.
> Patients with de novo intermediate- or high-grade NHL, except for  
> intermediate subtype of follicular large cell NHL.
> Complete tumor resection.
> Lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia).
> Co-expression of the CD5, CD19, CD20, and CD23 surface antigens.
> One of the following histologically or cytologically confirmed  
> malignancies:.
> Diagnosis of multiple myeloma (MM).
> Pretransplant cytoreductive chemotherapy allowed for patients with  
> relapsed or refractory disease.
> Age 18 and over.
> No other concurrent investigational therapy or approved anticancer  
> therapy.
> Are enrolled in another pregnancy treatment study.
> No clinically significant, multifocal, uncontrolled cardiac  
> dysrhythmias.
> 65 and over (for patients at HOVON centers).
> Patients who have had bone marrow transplantation (with or without  
> TBI).
> Non-myelosuppressive treatment IND medications.
> No prior breast cancer except lobular carcinoma in situ (LCIS).
> Cytomegalovirus (CMV) end organ disease e.g., retinitis, hepatitis,  
> gastroenteritis.
> Positive pelvic washings.
> Recurrent or nonhealing ulcer (Grade II, Wagner scale).
> Expectation of having back surgery in the next 6 months.
> No concurrent full-dose oral or parenteral anticoagulants except to  
> maintain patency of permanent indwelling IV catheters.
> Drugs that could cause peripheral neuropathy including phenytoin,  
> hydralazine, metronidazole, and nitrofurantoin.
> Mediastinal or hilar lymphadenopathy.
> See Disease Characterisics.
> At least 7 days since prior biologic agents and recovered.
> Advanced ARC or AIDS as defined by CDC.
> Have symptomatic CNS involvement.
> Significant cardiac disease (New York Heart Association Stage III or  
> IV).
> Completion of complete blood count, urinalysis, liver and thyroid  
> function tests, and pregnancy tests, with no evidence of significant  
> lab abnormalities.
> No prior second malignancies except for basal cell carcinoma of the  
> skin.
> Any other clinical condition that would preclude compliance with  
> dosing requirements.
> No evidence of distant metastases or histologically or cytologically  
> confirmed lymph node metastases.
> Cannot follow the visit or dosing schedule or are not available for  
> 1 year.
> PT in the normal range for the laboratory.
> No pain of multiple etiologies at the proposed treatment site (e.g.,  
> pain of neuropathic and muscular or skeletal origin).
> At least 30 days since other prior experimental drugs.
> At least 2 weeks since other prior non-cytotoxic therapy.
> No concurrent known appetite stimulants (e.g., megestrol or  
> dronabinol).
> History of grade 2 or higher peripheral neuropathy.
> No concurrent raloxifene, including for osteoporosis.
> Previously treated with tamoxifen for 57-66 months.
> Are in good general health and meet laboratory test requirements.
> The patient has uncontrolled seizure disorder, active neurological  
> disease, or  neuropathy.
> Diagnosis of Binge Eating Disorder.
> Any other medication felt to be immunomodulatory or felt to exhibit  
> significant hepatotoxicity or hematologic or renal toxicity by study  
> investigators.
> Availability of a HLA-A, B, and DR identical family donor OR HLA-A,  
> B, and DR genetically matched unrelated donor.
> Health-related illness that would prevent the patient from  
> completing the research study.
> Tuberculin test (PPD) positive >= 5 mm.
> ECOG 0-1 (0-2 if albumin is at least 0.85 times lower limit of  
> normal and weight loss within 3 months before diagnosis is no  
> greater than 10%).
> Intend to start antiretroviral therapy within 14 days of study entry.
> Chronic suppressive therapy for herpes simplex virus,  
> cytomegalovirus, Candida albicans, and Salmonella.
> At least 24 hours since prior use and no concurrent use of any of  
> the following:.
> Must be healthy based on medical exam, laboratory tests and  
> electrocardiogram.
> Prior intravesical therapy allowed if administered prior to  
> cystectomy.
> Concurrent hormone replacement therapy allowed provided therapy was  
> initiated prior to study enrollment.
> HIV isolate with an AZT IC50 > 50 times that of the sensitive type  
> strain.
> No prior preoperative pelvic radiotherapy for rectal cancer.
> Have a clinically significant abnormal 12-lead ECG that may  
> jeopardize the subject's ability to complete study.
> Ductal carcinoma in situ or lobular carcinoma in situ at the  
> surgical resection margin allowed.
> No t(8;21) alone or in combination with other abnormalities.
> Requires a minimum of 3 days of IV medication.
> Specified lab parameters.
> Signed, informed consent from parent or legal guardian for patients  
> less than 18 years of age. Prior Medication: Allowed: Local  
> treatment for Kaposi's sarcoma.
> Have or have had pancreatic disease.
> Cardiovascular: Normal ECG; Ejection fraction at least 55% OR  
> Fractional shortening at least 30%.
> No concurrent hormonal therapy except for the following:.
> Alpha-fetoprotein level greater than 30 ng/mL.
> Documentation of previously resected primaries must be based on  
> pathologic results of the resected tumor.
> Concurrent regular treatment for migraine and gastrointestinal  
> hemorrhage allowed.
> Endocrine therapy: Prior hormonal therapy allowed No concurrent  
> hormonal therapy.
> HIV-negative, sexually active women living in social and sexual  
> proximity to men at high risk for acquiring HIV infection.
> No history of allergy to platinum compounds.
> Residual disease after autologous transplantation.
> "High-risk" myelodysplastic syndrome, including:.
> Histologically confirmed localized Ewing's sarcoma or peripheral  
> primitive neuroectodermal tumor (PNET) of the bone or soft tissues.
> Are willing to undergo HIV testing.
> Prior valproic acid.
> Documented CD45 expression in patients with relapsed disease.
> M0 with unresectable primary tumor.
> No prior oblimersen.
> No positive lymph nodes found among at least 6 axillary nodes  
> examined on axillary node dissection.
> Surgically treated carcinoma in situ of the cervix.
> No infection with Burkholderia cepacia.
> unable or unwilling to take folic acid, vitamin B12 supplementation,  
> or dexamethasone.
> Histologically confirmed vitreal lymphoma with measurable  
> intracranial tumor.
> Any condition or any medication which may interfere with the conduct  
> of the study.
> Active suicidal ideation or psychosis.
> No concurrent epoetin alfa (e.g., Procrit; or Aranesp;).
> Have any medical conditions or past treatments that the study  
> investigator believes would make the patient unsuitable for the study.
> Less than 5 cm in largest dimension.
> The patient has undergone major thoracic or abdominal surgery within  
> 30 days (to allow for a full recovery)prior to the first infusion of  
> cetuximab.
> Currently a patient in the Omaha VA Medical Center, Substance Abuse  
> Treatment Center (SATC) or at Catholic Charities Campus for Hope.
> No concurrent bisphosphonates, except in the following cases:.
> No major medical illness.
> Myeloma protein in serum.
> Documented HIV infection or AIDS.
> Histologically confirmed breast cancer with metastases.
> Bilirubin normal.
> No prior radiotherapy to indicator lesion.
> Epithelioid sarcoma.
> Experimental agents within the past 30 days.
> MUGA or echocardiogram normal while on trastuzumab.
> Histologically or cytologically confirmed hematologic malignancy  
> refractory to standard therapy or for which no known effective  
> therapy exists.
> See Radiotherapy.
> Documented or suspected fungal esophagitis in patients with symptoms  
> of esophagitis.
> History of acute pancreatitis within the past 2 years.
> Have or have had an AIDS-related illness (except Kaposi's sarcoma or  
> Pneumocystis carinii pneumonia).
> No other concurrent non-cancer-related illness that would preclude  
> study therapy.
> Women of childbearing age are excluded.
> Migraine headache meeting International Headache Society criteria 3  
> or more times a month for more than 1 year.
> No insulin dependent diabetes mellitus.
> Women cannot be pregnant or breastfeeding.
> Patients must be willing and able to comply with the study protocol  
> for the duration of the study,.
> At least 4 weeks since prior chemotherapy (6 weeks since prior  
> nitrosoureas or mitomycin) and recovered.
> At least 4-6 weeks since prior therapy.
> Recurrent or persistent following standard surgery, radiotherapy,  
> and chemotherapy, including fluorouracil and irinotecan.
> At least 1 week since prior biologic therapy or immunotherapy and  
> recovered.
> Persistent or progressive disease by post-transplant day 90-360.
> No pulmonary disease that would preclude study participation.
> Radiographic evidence of recurrent or progressive supratentorial  
> tumor.
> Histologically or cytologically confirmed anaplastic astrocytoma.
> Not actively participating in another clinical drug trial.
> Lymph node positive gastric cancer.
> Require certain drugs.
> Previous diagnosis of multiple myeloma based on standard criteria.  
> Tests need not be performed within 30 days of registration.
> Have an LDL cholesterol <125 mg/dL on 2 visits at least 4 weeks  
> apart during the 10 month lead in phase.
> T-cell lineage ALL regardless of the WBC.
> Have a viral load of more than 5,000 copies/ml.
> Not on active Vitamin D therapy for at least 4 weeks prior.
> Treatment, maintenance, or chemoprophylaxis for opportunistic  
> infections, as clinically indicated unless otherwise prohibited by  
> the protocol.
> No history of deep venous thrombosis not related to trauma or  
> pregnancy.
> Patients with compensated cirrhosis without previous history of  
> ascites or edema.
> Partially resected stage IIIB disease allowed provided a measurable  
> lesion remains.
> Radiation therapy within 3 weeks before the first dose of study drug.
> PT no greater than 6 seconds above control.
> No prior noncompliance to medical regimens or potential unreliability.
> No more than 10 bone metastases.
> No active infection or uncontrolled infection.
> No other concurrent antineoplastic or cytotoxic therapy.
> No prior or concurrent malignancy within the past 3 years except  
> cutaneous basal cell skin cancer.
> History of ALT elevations over 3 X baseline level.
> Bisphosphonate therapy initiated prior to study entry is allowed,  
> however, initiation of bisphosphonates following study entry is not  
> allowed.
> At least 4 weeks since prior surgery (except diagnostic surgery) and  
> recovered.
> Able to speak and understand English.
> No previous surgery for treatment of TMD pain.
> Have taken hydroxyurea in the past 4 months.
> Ability to understand and cooperate with study procedures.
> Use of marrow toxic agents with ganciclovir and nephrotoxic agents  
> with foscarnet is discouraged, and alternative treatment should be  
> used whenever possible.
> Concurrent antiseizure medications allowed.
> No prior nucleoside analogue therapy.
> More than 3 weeks since prior NSAIDs.
> No other malignancy within the past 5 years except adequately  
> treated carcinoma in situ of the cervix or nonmelanoma skin cancer.
> Fractional shortening at least 30% by echocardiogram.
> Creatinine no greater than 2.0 mg/dL OR.
> Prior ddI.
> Are male or female and are at least 13 years old (or 18 if local  
> requirement) and can provide consent from parent or guardian if  
> under 18.
> Current treatment with psychotropic medications, including  
> disulfiram (Antabuse) (excluding short-term use of benzodiazepines  
> for detoxification).
> At least 10 mm by spiral CT scan or MRI.
> Patient has a positive urine test at screening for presence of  
> illicit drugs or alcohol abuse during the past 12 months.
> No antiretroviral therapy within the past 6 months.
> Characteristic clinical symptoms and signs of AIDS dementia complex.
> Stage II-IV at diagnosis.
> Neuropathy due to any other cause besides HIV infection.
> No dementia or altered mental status that would preclude giving  
> informed consent.
> At least 4 weeks since prior chemotherapy (6 weeks for nitrosourea  
> or mitomycin) and recovered.
> Stable medical condition for 3 months.
> No other prior malignancy or uncontrolled systemic disease that  
> would preclude study participation.
> Patient has stable residence.
> Have had a serious illness or injury within 30 days of screening.  
> Treatment must have been completed for 14 days prior to study entry.
> Condition precludes waiting to search and find a donor in the  
> National Marrow Donor Registry.
> Other: No concurrent potential nephrotoxic or ototoxic drugs (e.g.,  
> aminoglycosides).
> No other uncontrolled malignancy.
> Must not require immediate radiotherapy.
> rising PSA.
> Cumulative anthracycline exposure > 300 mg/m2.
> BCR/ABL translocation present by fluorescence in situ hybridization.
> Positive circulating hepatitis B virus antigen.
> No uncorrected hypokalemia.
> IV foscarnet.
> Up to 14 days of systemic therapy for minor opportunistic infections  
> such as candidiasis, mucocutaneous Herpes simplex or cutaneous  
> Herpes zoster infections.
> Women at least 18 years old, with performance status 0-2.
> Autoimmune hepatitis (FANA titer >= 1:160 and anti-smooth muscle  
> antibody titer >= 1:160).
> Any other concurrent condition that interferes with the absorption,  
> distribution, metabolism, or excretion of drugs.
> Are between 18 and 65 years of age.
> Smallpox vaccination in 1990 or more recently.
> PT 2-4 seconds greater than upper limit of normal (ULN).
> Age: Over 14.
> Concurrent antacids allowed provided they are administered at least  
> 6 hours before or 90 minutes after topotecan.
> Any past history of heart failure;.
> Major depression likely to interfere with evaluation or protocol  
> compliance. Concurrent Medication: Excluded:.
> No concurrent palliative surgery.
> Failed anthracycline-based chemotherapy.
> No concurrent medication that affects QT/QTc and/or induces torsades  
> de pointes.
> No investigational agents within 30 prior to the first dose of study  
> drug or 5 half-lives of the action of the agent, whichever is longer.
> Use of low molecular weight heparin (LMWH) in the previous 6 hours  
> before PCI.
> No prior chemotherapy for pancreatic adenocarcinoma.
> Normal 12 lead ECG.
> Symptoms not significantly relieved by antimicrobial agents,  
> anticholinergic drugs, or antispasmodics.
> Abuse alcohol and other drugs.
> Histologic and/or nuclear grade 2-3.
> Urine protein no greater than trace OR.
> Have a history of invasive fungal infection.
> Patient has signs or symptoms of acute infection requiring systemic  
> therapy.
> Organ preservation desired.
> More than 25% increase in bidimensionally measurable soft tissue  
> metastases.
> No concurrent participation in another phase III lung cancer  
> treatment trial.
> Poorly controlled hypertension.
> No active atherosclerotic cardiovascular disease (angina,  
> claudication).
> Patients with a hypersensitivity to Halichondrin B and/or  
> Halichondrin B-like compounds.
> Known or suspected impairment of immunologic function including, but  
> not limited to, clinically significant liver disease.
> No prior multi-drug resistance inhibitor.
> Stratum 2:.
> Negative pregnancy test HIV positive allowed.
> ZARNESTRA may interfere with coumadin dosing and patients who are  
> taking this combination will require more frequent monitoring of  
> their PT, PTT and INR.
> Enrolled on CALGB-89803 and must fall into 1 of the following  
> categories:.
> Confirmed diagnosis of cancer and currently receiving chemo.
> No multifocal or bilateral breast cancer.
> Documented, signed and dated informed consent to participate in this  
> trial prior to any study related procedures being performed.
> Any other major illness or condition that, in the investigator's  
> opinion, places the patient at undue risk by participating in the  
> study.
> Life expectancy greater than 3 months.
> No concurrent CYP3A4 inhibitors or inducers.
> Triglycerides < 200 mg/dl.
> Sexual intercourse with men or at least 5 male or female partners in  
> the 5 years prior to enrollment.
> Individuals unable to attain the test positions with active neck  
> motions.
> First regimen must have contained cisplatin or carboplatin.
> Karnofsky Performance Status >=60.
> No more than 10 weeks since completion of curative surgery.
> No concurrent radiotherapy to sole measurable lesion.
> CD4 count at least 50 cells/mm^3.
> No known coagulopathy/anticoagulant use.
> Concurrent hydroxyurea allowed during the first 2 courses of study  
> therapy in patients with rapidly progressing disease.
> Have had a recent serious illness, including pancreatitis or  
> peripheral neuropathy.
> Previously treated with at least 1 chemotherapy regimen.
> OR Sexual partner of someone with the above criteria.
> Age 6-12 months: greater than 100,000/mm^3.
> Hodgkin's lymphoma and anaplastic large cell lymphoma eligible.
> Premenopausal for oral contraceptive stratum.
> Backpain within the last 24 hours.
> AML arising from myelodysplastic syndromes or similar hematological  
> conditions.
> No other malignancy within past 5 years except inactive carcinoma in  
> situ of the cervix or nonmelanoma skin cancer.
> Ability to communicate, participate, and comply with the  
> requirements of the study.
> No clinically significant neuropathy.
> At least 3 months since prior radiotherapy except for palliative  
> radiotherapy to bone lesions.
> Not amenable to curative surgery or radiotherapy.
> No prior type 1 hypersensitivity or anaphylactic reactions to murine  
> products, rituximab, or radioimmunoconjugated anti-CD20 antibody  
> infusion.
> Already enrolled and in active follow-up in PACTG 219C.
> AST and ALT less than 1.5 times normal.
> You have active infection or other serious condition.
> History of seizure disorder.
> No cardiac arrhythmias requiring medical treatment.
> No more than 3 days abstinence/week.
> Prior orchiectomy OR.
> Evidence of progressive disease within 6 months after last dose of  
> irinotecan.
> Surgically staged as stage III or IV at initial diagnosis.
> Calculated creatinine Clearance < 30 ml/min at baseline.
> No history of tubal ligation.
> Measurable or evaluable disease by MRI or CT.
> Coagulation profile normal.
> Cytotoxic chemotherapy for malignancy.
> Interferons, immunomodulators (other than colony stimulating  
> factors), or CMV hyperimmune globulin within 30 days prior to study  
> entry.
> Stage III with suboptimal disease after initial surgery.
> Membership in a vulnerable population (e.g. pregnant woman,  
> prisoner, etc.).
> No unstable ventricular arrhythmias.
> No concurrent new hormonal therapy.
> OR History of opportunistic disease fulfilling the CDC surveillance  
> definition of AIDS.
> History of hypersensitivity or significant intolerance to  
> aminoglycosides, macrolide antibiotics, or colony stimulating factors.
> Unresectable stage IIIB (e.g., pleural effusion) not suitable for  
> combined modality therapy OR.
> Radiographically documented metastatic disease.
> Positive CSF cytology.
> Fertile patients must use effective contraception during and for 12  
> months after study therapy.
> At least 1 regimen must have contained a platinum agent (i.e.,  
> carboplatin or cisplatin).
> Presenting for a well-woman visit, annual Pap smear, or family  
> planning.
> First episode of sight-threatening CMV retinitis.
> Known hormone receptor status.
> Medications known to cause gastrointestinal irritation or alteration  
> of gastrointestinal motility or absorption should be avoided if  
> possible.
> Variegate porphyria and hereditary coproporphyria eligible but  
> analyzed separately.
> Gastrointestinal (GI) or genitourinary (GU) bleeding of clinical  
> significance within 6 weeks prior to randomization.
> Oxygen saturation at least 90% on room air.
> Are participating in a clinical trial of any investigational drug.
> Primary testicular androgen suppression (e.g., LHRH agonist or DES)  
> continues during study.
> Known or documented brain metastases.
> Topical, oral, and systemic corticosteroids.
> Alkaline phosphatase less than 2.5 times ULN (for patients with  
> documented benign disease).
> Mixed malignant glioma.
> Use of neuroleptics or narcotic analgesics within 4 weeks prior to  
> screening.
> Diagnosis of idiopathic myelofibrosis or other myeloproliferative  
> disorder with myelofibrosis.
> Proof of HIV infection.
> Under 366 days at diagnosis.
> Chemotherapy, hormonal therapy, or other immunotherapy.
> Bone marrow aspiration and biopsy within the past 42 days.
> Metastatic disease with documented progression.
> Measurable or evaluable indicator lesion.
> Are at least 13 years old. (Need consent of parent or guardian if  
> under 18.).
> Patients who have received any investigational agent within 4 weeks  
> of enrollment.
> More than 6 months since prior radiotherapy for head and neck cancer.
> Zidovudine (AZT) for > 6 months.
> Receiving a transplant from a living related donor who is ABO (blood  
> type) compatible and haploidentical (3,4, or 5 antigen match by  
> serologic typing).
> No hypocellular bone marrow (no greater than 15% cellularity) or  
> marked decrease in 1 or more hematopoietic precursors.
> Must weigh at least 50 kilogram.
> Bone marrow blasts greater than 5% of nucleated cells.
> No concurrent immunomodulating agent.
> NNRTI therapy prior to study entry (with the exception of Group D).
> Myelotoxic agents for malignancy or other condition.
> Alkaline phosphatase less than 2 times ULN* NOTE: * Less than 5  
> times ULN if documented liver disease.
> Any investigational drug during the 4 weeks prior to randomization.
> Current neoplasm other than Kaposi's sarcoma.
> Any immunomodulator therapy within 30 days prior to entry.
> Grades I, II, or III.
> Patients who have undergone prior resection of recurrent or  
> progressive tumor require evaluable disease only.
> Positive PPD.
> Rifampin, rifabutin, astemizole, loratadine, or terfenadine within  
> 21 days prior to initial study drug dose.
> Shortening fraction or ejection fraction greater than 40% of normal  
> value for age by echocardiogram or radionuclide scan.
> Tanner Stage of Development: Stage 1.
> FSP less than 40.
> Histologically confirmed refractory solid tumor and/or lymphoma.
> Unable to participate in 5 lifestyle intervention meetings occurring  
> over a one year period.
> CMV serology (IgG) positive (CMV bDNA cohort and CMV-virology cohort).
> Written informed consent.
> Hypertrophic cardiomyopathy (obstructive or non-obstructive).
> Prophylactic therapy for Pneumocystis carinii pneumonia.
> No other major medical illness or psychiatric impairment that would  
> preclude study compliance.
> Are receiving anti-HIV medications at study entry.
> No concurrent drugs that would preclude absorption of oral topotecan.
> Evidence of evolution to AML (e.g., refractory anemia with excess  
> blasts (RAEB) or RAEB in transformation).
> Other: No prior cancer therapy that would preclude study.
> Concurrent chemotherapy allowed after surgery and before vaccination.
> Temperature more than 38 degrees and/or drenching night sweats for  
> more than 1 month; watery diarrhea for 2 or more weeks; weight loss  
> of more than 10 percent.
> Intact, unbroken skin over the painful area(s) to be treated.
> Have taken drugs that might affect the immune system, within 4 weeks  
> prior to study entry.
> History of grade 2 or worse liver abnormality.
> A stable dosage of non-excluded medications for at least 2 weeks  
> prior to the Screening Visit.
> Willingness and ability to complete interviews.
> No concurrent sulfonylurea agent for diabetes or antiarrhythmic  
> agents.
> Amyloidosis.
> Naproxen.
> Also eligible after two to four cycles of conventional dose salvage  
> chemotherapy, regardless of response.
> Biologic response modifiers (alpha interferon, IL-2, immune  
> modulators). Required:.
> No prior imatinib mesylate (stratum II).
> Active immunization within 21 days prior to study entry.
> No prior ipsilateral or contralateral invasive breast cancer.
> No concurrent investigational ancillary therapy.
> At V1, the subject must demonstrate a baseline FEV1 within >45% and  
> <75% of predicted for their height, age, gender, and race.
> No other concurrent immune modulators.
> Hepatic: Serum bilirubin < 2.0 mg/dL; AST and ALT < 2 x ULN w/o  
> liver metastases or <5 x ULN w/liver metastases.
> Comatose.
> No grade 2 or greater neuropathy.
> Unwilling to comply with study design. Concurrent Medication:  
> Excluded:.
> No impending spinal cord compression.
> Platelet count at least 50,000/mm3.
> Liver enzymes no greater than upper limit of normal.
> Interferon or interleukin.
> In second or greater relapse.
> Hematopoietic progenitor cell transplant subjects with chronic or  
> Grade II-IV acute GVHD being treated with high dose  
> immunosuppressive therapy.
> More than 4 weeks since prior systemic therapies for prostate cancer.
> Alcoholism or drug abuse within 12 months of study entry.
> Sciatica persisting 3 or more months after physician visit.
> Ejection fraction of at least 40% by radionuclide angiogram  
> echocardiogram.
> Erythropoietin, G-CSF or GM-CSF within 30 days prior to entry.
> Alkaline phosphatase no greater than 4 times ULN if AST/ALT less  
> than ULN.
> Have a disease affecting the red blood cells.
> Have a fever or chronic diarrhea within 30 days of study entry.
> Have phenotypic sensitivity to atazanavir and LPV/RTV.
> No known brain metastases or primary brain tumors.
> Active opportunistic infection or febrile illness with temperature  
> >= 38.5 C within 3 days prior to study entry.
> Prior use of the combined treatment of the 2 study drugs used in  
> this study.
> Positive syphilis serology.
> Must be negative for BR96 antibodies in serum.
> No clinical immunodeficiency.
> Women age 18 years or older.
> At least 1 week since prior hormonal therapy for this disease.
> No clinically serious active infection.
> Histological confirmation waived for brain stem gliomas.
> Are a woman and are pregnant or breastfeeding, intend to become  
> pregnant within the next 2 years or a woman not using effective  
> birth control.
> No prior mediastinal irradiation.
> ADAS-cog score of at least 12 and MMSE score of 10 to 26.
> Karnofsky Performance Rating Scale below 50 or physical limitations  
> or illness severity sufficient to preclude participation in  
> outpatient group psychotherapy.
> Agree to avoid becoming pregnant or causing someone to become  
> pregnant while participating in the study.
> Prior prostatic radiotherapy allowed.
> HIV or Hepatitis.
> The presence of cannabis is not exclusionary unless the investigator  
> believes its use will interfere with patient compliance.
> Therapy was no more than 6 months in duration.
> Cervical intra-epithelial neoplasm or FIGO stage I carcinoma of the  
> cervix.
> No uncontrolled or significant cardiac disease.
> Currently in behavior therapy for obsessive compulsive disorder.
> Agree to abstinence or use of an effective barrier method (e.g.,  
> condom) of birth control.
> Appearance of new lesions on bone scan.
> Prior recombinant erythropoietin and/or G-CSF for AZT-related bone  
> marrow suppression.
> No metastatic disease by physical exam and chest x-ray or CT scan of  
> the chest.
> Evidence of regional lymph node metastases (N1-N3).
> Are between ages 18 and 55.
> Responsive or stable disease after prior induction chemotherapy  
> comprising cisplatin or carboplatin AND etoposide or irinotecan.
> Progressive lymphocytosis with an increase of more than 50% over a 2- 
> month period or anticipated doubling time of less than 6 months.
> No prior hemodialysis.
> Diffusion capacity greater than 50% predicted (corrected for  
> hemoglobin) if symptomatic.
> Previously treated with allogeneic stem cell or bone marrow  
> transplantation for primary disease.
> Karnofsky greater than 70%.
> No prior radiotherapy to study lesion, unless evidence of disease  
> progression.
> One of the following stages:.
> Platelet count at least 100,000/mm^3 for good marrow reserve  
> (150,000/mm^3 for poor marrow reserve).
> 4 to 21.
> At least 4 weeks since prior interferon.
> Previously treated brain metastases in continued response to  
> radiotherapy and/or surgery for at least 2 months allowed.
> No HIV or HTLV-1 associated lymphomas.
> Allowed as prophylaxis for Pneumocystis carinii pneumonia (PCP):.
> No other concurrent primary malignancy except carcinoma in situ or  
> nonmelanoma skin cancer.
> Presence of any AIDS-defining neoplasms (excluding Kaposi's sarcoma)  
> such as central nervous system (CNS) lymphoma.
> Positive urine pregnancy test.
> More than 2 weeks since prior surgery, other than biopsy or  
> placement of venous access device.
> Recovered from any prior surgery.
> More than 12 months since prior coronary/peripheral artery bypass  
> graft surgery.
> No prior thoracic irradiation.
> Histologically or cytologically confirmed solid tumor or hematologic  
> malignancy.
> No pre-existing convulsive disorder.
> Unwilling or unable to be fully evaluated for all follow-up visits.
> At least 30 days since prior systemic corticosteroids.
> Have a history of a neurologic disease unrelated to HIV infection.
> Synchronous primary endometrial cancer or history of primary  
> endometrial cancer.
> Patient must have pneumonia as documented by relevant signs and  
> symptoms and a positive chest X-ray.
>> 3 prior regimens.
> Persistent lymphoma by physical examination, radiographic studies,  
> bone marrow evaluations, flow cytometry, or polymerase chain reaction.
> Estrogen and progesterone receptor status known.
> Underlying clinical condition that precludes study completion or  
> places the patient at significant risk.
> Use of illegal drugs or legal drugs for recreational purposes or  
> excessive use of alcohol.
> Extramedullary disease outside liver or spleen.
> Dapsone is permitted but discouraged.
> At least 3 weeks since last major surgery (a lesser period is  
> acceptable if deemed in the best interest of the patient).
> More than 2 weeks since prior minor surgery.
> No prior chemotherapy or radiosensitizers for cancers of the head  
> and neck.
> Diagnosis of stage IV melanoma.
> Prior radiotherapy to study lesions allowed if there is evidence of  
> disease progression.
> No evidence of disease after prior standard treatment with curative  
> intent.
> At least 4 weeks since prior HRT.
> Concurrent oral or IV bisphosphonates for bony metastases are allowed.
> Women must not be pregnant or lactating.
> No medical condition that would interfere with oral administration  
> of erlotinib.
> SGOT no greater than 3 times upper limit of normal (ULN) (no greater  
> than 5 times ULN if liver metastases present).
> Has taken Aricept, Reminyl, or Exelon in the last 5 weeks.
> WBC at least 3,000/mm3.
> Pain for 3 months or longer.
> No other prior malignancy within the past 5 years except adequately  
> treated basal cell or squamous cell skin cancer or carcinoma in situ  
> of the cervix.
> Antimycobacterial drugs other than rifabutin.
> Larynx.
> Participation in other investigational studies within 30 days of the  
> renal transplant.
> For patients on corticosteroids:.
> No known hepatitis B virus.
> Surgery: No prior treatment other than transurethral prostatectomy;  
> No prior orchiectomy.
> Are 16 to 35 years of age.
> Ewing's sarcoma.
> Treatment with bone active agents such as fluoride or  
> bisphosphonates within the previous 2 years.
> Anticoagulant therapy.
> Toxicity Criteria for sensory neuropathy.
> No concurrent hormonal agents, except corticosteroids.
> Age less than 18 years.
> Prior development of a moderate or sever rash or any desquamation  
> while taking thalidomide.
> Children must be able to retain liquids at the time of enrollment.
> Suspected septicemia caused by coagulase-negative staphylococci.
> Failed or ineligible for standard therapy with iodine I 131 and/or  
> surgery.
> Distant metastases with measurable disease in breast or lymph nodes.
> No ductal cancer in situ or multicentric invasive ductal cancer.
> Chest wall tumors with ipsilateral pleural effusions or ipsilateral  
> pleural-based secondary tumor nodules allowed.
> Rheumatoid Arthritis for greater than 1 year from the time of  
> initial diagnosis of RA.
> Stage III (any T3b-T4, N2 or N3, M0).
> Patients must meet criteria for either platinum-resistant or  
> platinum-sensitive ovarian or peritoneal cancer.
> History of localized disease with prior definitive radiotherapy or  
> surgery.
> Previous systemic infection including influenza during this pregnancy.
> No life threatening infection.
> Prior steroid therapy for less than 2 weeks allowed.
> Willing to fast and complete clinical and laboratory evaluations.
> Expected survival of three months or longer.
> At least 4 weeks since prior immunotherapy other than interferon,  
> donor lymphocyte infusion, or pentavalent vaccine Concurrent  
> interferon allowed.
> History or evidence of drug or alcohol abuse.
> No other known condition that would preclude study participation.
> May include neurofibromatosis type I or II.
> Ability and will to participate in study for 4 years.
> Evidence of cytomegalovirus retinitis or colitis.
> History of acute or chronic pancreatitis, gout, or uric acid  
> nephropathy.
> Isoniazid for treatment of tuberculosis, with permission of the  
> protocol chair, when given in conjunction with pyridoxine.
> No concurrent corticosteroid therapy.
> No concurrent radiotherapy except to symptomatic or potentially  
> disabling bone lesion accompanied by other measurable disease.
> Must be a candidate for potential future pulmonary resection.
> Complete or partial remission following 1 induction course with  
> adverse cytogenetic abnormalities at diagnosis.
> Multifocal intraperitoneal tumors.
> Steroids in excess of physiologic replacement doses.
> BCG vaccines.
> Immunoglobulin administration or use of experimental agent within  
> the past 2 months.
> No concurrent tobacco use (e.g., cigarette, cigar, pipe, or chewing  
> tobacco).
> Cirrhosis.
> Normal urinalysis.
> No American Society of Anesthesiologists IV/V disease classification.
> Adequately treated in situ carcinoma of the cervix uteri.
> At least 1 year since prior corticosteroids, estrogens, progestins,  
> or any other steroid hormone.
> At least 1 month since prior beta-carotene compounds.
> No active opportunistic infection.
> Antiviral chemotherapy.
> Chemotherapy administered as a radio-sensitizer does not count as 1  
> regimen.
> Malabsorption.
> Bilirubin no greater than 2 times upper limit of normal* (ULN)  
> (unless due to Gilbert's syndrome).
> Cannot take medications by mouth or absorb drugs.
> Cranial spinal: 1800 cGy.
> No chronic hepatitis B.
> Prior investigational agents incorporated into prior systemic  
> chemotherapy allowed.
> No prophylactic hematopoietic growth factors (e.g., filgrastim (G- 
> CSF)).
> Consent of parent or guardian required. Note:.
> Chemotherapy: At least 4 weeks since prior methotrexate or  
> cyclophosphamide.
> Fertile patients must use effective contraception during and for at  
> least 4 weeks after study participation.
> Tolerating zidovudine (AZT) at time of study entry.
> Soft tissue primitive neuroectodermal tumor (PNET).
> SPV-30.
> No current history of alcohol or drug abuse.
> No concurrent anticoagulants other than those required to maintain  
> the patency of indwelling IV catheters.
> No other active cancer except previously treated carcinoma in situ,  
> non -melanoma skin cancer, or stage I prostate cancer.
> Have consent of parent or guardian if less than 18 years old.
> History of coronary artery disease and/or congestive heart failure  
> allowed if medical management of condition has been stable within  
> the past 6 months.
> Primary refractory AML for which no standard therapy exists.
> High-risk disease, defined as stage III or IV extragonadal germ cell  
> tumors.
> No known hypersensitivity to retinoids or retinoic acid derivatives  
> or to interferon or any component of the injection for this study.
> Have serious heart problems. Patients with high blood pressure  
> controlled by blood pressure medication but no heart disease may be  
> eligible for this study.
> Traumatic brain injury with loss of consciousness of > 24 hours and/ 
> or skull fracture.
> Mediastinal (thymic) large cell.
> Direct bilirubin no greater than 1.5 times ULN.
> No medical contraindication to study therapy.
> No severe diabetes.
> Other: At least 15 kg body weight No severely compromised clinical  
> or nutritional state.
> No marked edema by MRI with significant shift that is not  
> anticipated to be corrected by resection.
> Treatment with biologic response modifiers (e.g., interferon,  
> interleukin) within 14 days prior to study entry. Prior Treatment:  
> Excluded:.
> Anti-HIV drugs other than the study drugs. Concurrent Treatment:  
> Excluded:.
> At least 14 days since other prior major surgery.
> More than 3 months since prior chemopreventive drugs (e.g.,  
> retinoids).
> Intestinal cryptosporidiosis.
> Transplant where a trial reduction of immunosuppressive drug  
> treatment is not feasible.
> No more than 1 prior chemotherapy regimen (phase II).
> Bone marrow specimen showing clumps of tumor cells accompanied by  
> elevated urinary catecholamines.
> Can identify a collateral informant who has frequent contact with  
> the subject.
> History of an AIDS defining illness by the Centers for Disease  
> Control (CDC) definition within 8 weeks prior to study entry.
> Planned revascularization.
> No prior congestive heart failure unless ejection fraction at least  
> 40%.
> No prior surgery for head or neck cancer.
> Bilirubin no greater than 2.0 mg/dL.
> No concurrent immunotherapy during and for 2 weeks after last  
> vaccination.
> Enrollment in HSC protocol #97-0695 "Rehabilitation Intensification  
> Post Hip Fracture".
> Suspicion of need for colectomy.
> No prisoners or parolees HIV negative.
> At least 28 days since prior imatinib mesylate.
> Systemic corticosteroids for > 21 consecutive days.
> Histologic proof of lymphoid malignancy with an expected complete  
> response rate of less than 20 percent OR have failed at least one  
> prior therapy.
> Have had an unexplained fever of at least 38.5 C for 7 days in a row  
> within 30 days prior to screening.
> No other active malignancy except basal cell skin cancer or  
> carcinoma in situ of the cervix.
> Diagnosis of acquired immune deficiency syndrome.
> Ongoing and/or maintenance therapy for opportunistic infection.
> Diagnosis of an unstable medical illness within the last 12 months.
> Currently residing in the community (own home,family member's home,  
> or small group home) and agreeing to 13 weeks of followup in the  
> study.
> Surgery: Patients are excluded if they have had major surgery either  
> during or within four weeks prior to study entry.
> No clinically significant arrhythmia by ECG.
> Zidovudine (AZT) within 7 days prior to administration of study  
> drug. Excluded for at least 4 weeks prior to drug administration:.
> Carcinoid asthma.
> Progesterone receptor status known.
> patients may take ganciclovir for treatment of CMV infections.).
> Recipients of grafts from an HLA-identical sibling.
> Age over 30 years.
> Previous surgeries for SDB, such as adenoidectomy and/or  
> tonsillectomy or other airway-related surgeries.
> More than 5% blasts in the bone marrow or peripheral blood unrelated  
> to recovery of normal hematopoiesis from prior chemotherapy.
> No uncompensated congestive heart failure.
> Severe dysfunction (CrCl less than 30 mL/min).
> Stage III/IV ovarian cancer.
> Must have received at least one prior chemotherapy regimen for  
> metastatic breast cancer.
> No prior trastuzumab.
> Cumulative history of oral glucocorticoid use for at least 6 months  
> over the last year prior to the Screening Visit (the 6 months do not  
> have to be consecutive).
> No active urinary tract infection.
> Study partner to accompany subject to all visits.
> Concurrent therapeutic anticoagulants (e.g., warfarin or heparin)  
> allowed provided there is no prior evidence of underlying  
> abnormality with PT, INR, or PTT.
> No disease invading the airways, aorta, pericardium, or lung.
> Greater than 3.5 g/dL for G peaks or greater than 2.0 g for A peaks.
> No history of any bleeding disorders.
> At least 6 months since prior oral retinoids (3 months for topical  
> retinoids to the face).
> Availability of at least 1 x 10^8 purged autologous mononuclear bone  
> marrow cells per kg of body weight.
> At least 6 months since prior high-dose chemotherapy regimen with  
> stem cell support.
> Patients receiving LHRH analogues must have testosterone level less  
> than 50 ng/dL.
> Pain in the knee of at least 3 or more on a 0 to 10 scale (0 none,  
> 10 extreme pain) within 2 weeks prior to study entry.
> Refractory anemia with excess blasts (RAEB) with IPSS score at least  
> 1.5.
> Aerosol ribavirin for short-term treatment of acute respiratory  
> syncytial virus (RSV).
> Biologic therapy: No prior trastuzumab.
> No uterine sarcomas (leiomyosarcoma), mixed mullerian tumors, and/or  
> adenosarcomas.
> Spinal muscular atrophy.
> Have had a reaction to an anticoagulant (such as warfarin or heparin).
> Reached an ACTG 240 defined endpoint, or are permanently off ACTG  
> 240 study treatment.
> Are breast-feeding and are unwilling to stop breast-feeding.
> At least 3 weeks since prior major surgery.
> At least 1 week since prior radiotherapy to less than 15% of bone  
> marrow.
> Adequate bone marrow, liver and renal functions.
> At least 3 weeks since prior surgery requiring general anesthesia.
> Grade 4 (for hematologic) or Grade 3 (for all other) toxicity.
> Elevated liver enzymes in the year preceeding enrollment.
> Adequate hematologic function.
> Unexplained diarrhea defined as three or more liquid stools per day,  
> persisting more than 7 days within 2 years prior to entry.
> Any disorders for which the study drugs are contraindicated  
> (didanosine (ddI)) is contraindicated in renal impairment, heart  
> disease, receiving renal dialysis.
> Must have evidence of metastatic disease, including either of the  
> following:.
> Transfusion dependent patients. Patients with any of the following  
> prior conditions are excluded:.
> Discordant histologies between nodal tissue and bone marrow on  
> presentation are eligible.
> Isolated CNS relapse not eligible.
> No concurrent hormonal therapy, including aromatase inhibitors, pure  
> antiestrogens, or progestational agents, for breast cancer.
> Localized, non-disseminated.
> Adults of reproductive potential and their partners must agree to  
> use effective contraceptive measures.
> Post-hydration creatinine less than 1.47 mg/dL.
> Prior anthracycline allowed if total dose no greater than 300 mg/m2.
> Patients must be disease free at time of enrollment based on the  
> following surgical criteria:.
> Significant anemia or thrombocytopenia or leukopenia.
> Token Test of the Multilingual Aphasia Examination score < 36.
> Have a CD4 count of at least 50 cells/mm3.
> Known HIV positive status or who have an AIDS-related illness.
> Hx of breast/estrogen-dependent cancer.
> More than 1 month since prior biologic therapy or immunotherapy.
> Prophylactic therapy for Pneumocystis carinii pneumonia (PCP) that  
> may cause leukopenia.
> Weight of 40 kg or greater.
> Presence of opsoclonus, myoclonus, and/or ataxia associated with  
> neuroblastoma considered eligible.
> No prior immunologic therapy directed at the cellular immune system.
> No other malignancy within the past 5 years except treated basal  
> cell or squamous cell skin cancer or carcinoma in situ of the cervix.
> A diagnosis of AIDS by CDC criteria.
> Marginal zone B-cell lymphoma.
> Negative urine toxicology screen (except for methadone or methadone  
> metabolites) within 14 days prior to study entry.
> Prior brain metastases are allowed provided the following are true:.
> Bilirubin less than 2.5 times normal.
> Progressive disease by physical exam, imaging studies, and/or rising  
> prostate-specific antigen (PSA) levels defined by at least 1 of the  
> following criteria*:.
> Drugs known to significantly interact with saquinavir and/or  
> nelfinavir. Patients must be protease inhibitor therapy naive.
> Creatinine clearance or radioisotope glomerular filtration rate  
> (GFR) at least 70 mL/min OR an equivalent normal GFR OR.
> Rituximab, Campath or other unconjucated therapeutic antibody within  
> 4 weeks before the first dose of study drug.
> At least 4 weeks since prior steroids or megestrol.
> Stage I, IIA, or IIB (T1-3, N0-1, M0).
> No known hypersensitivity to phenylethane compounds.
> Locally advanced, unresectable disease.
> Fertile patients must use effective contraception during and for at  
> least 30 days after study participation.
> HIV infection diagnosed by HIV seropositivity and confirmed by  
> Western blot.
> Leukotriene inhibitors (i.e., zafirlukast and zileuton).
> At least 4 weeks since prior immunotherapy or biologic therapy.
> Progression of disease within past 4 weeks by radiological evidence.
> Creatinine no greater than 1.5 mg/dL (urinary diversion allowed).
> No known uncontrolled CNS metastases.
> No prior estramustine or suramin.
> Study therapy must begin within 5 weeks of diagnosis.
> Biopsy-confirmed aphthous ulceration of the mouth or esophagus  
> lasting at least 2 weeks.
> Tension.
> Start preventive treatment for Pneumocystis carinii pneumonia (PCP)  
> within 30 days prior to study entry, if CD4 cell count is below 200  
> cells/microL.
> Tumors tested by FISH must be positive by the specific FISH assay  
> for genetic amplification of HER2.
> Congenital long QT syndrome;.
> No poor nutritional status unlikely to be restored to fair status  
> within 3 weeks.
> Zubrod 0-1.
> Metaplastic carcinomas allowed.
> Histologically confirmed hepatocellular cancer (HCC).
> T2, N0, M0 if primary lesion at least 3 cm.
> Prophylaxis for Mycobacterium avium intracellulare.
> No concurrent phenytoin, carbamazepine, rifampin, barbiturates, or  
> Hypericum perforatum (St. John's Wort).
> Have had a major organ transplant and still have the graft.
> No other concurrent antitumor chemotherapy.
> Patients with low grade lymphoma or CLL will only be eligible if  
> they failed two chemotherapy regimens and have stage IV disease.
> No active or recent uncontrolled bleeding.
> Active therapy with investigational drugs other than treatment for  
> HIV disease, except with approval of the sponsor.
> Acute or chronic meningitis based on any etiology other than  
> cryptococcosis.
> No acute or chronic infections (e.g., malaria).
> Protease inhibitors. NOTE:.
> Babies will not be eligible for this study if they:.
> HIV antibody positive by ELISA or Western blot assays.
> Concurrent intermittent vaginal estrogens allowed if other local  
> measures for intractable vaginal atrophy are insufficient.
> HIV positive as determined by ELISA, Western Blot, or other  
> federally approved HIV test within the past 21 days.
> Any HIV-1 protease inhibitor therapy prior to study entry (e.g.,  
> saquinavir, ritonavir, indinavir, nelfinavir, 141W94).
> No CNS or gonadal involvement.
> Major medical or neurological disease.
> Excessive alcohol consumption or evidence of drug use.
> Recovered from prior cancer therapy.
> Sulfadimidine.
> Cytologically positive effusion.
> Spinal cord injury at or above the T10 spine.
> AST or ALT <2.5 times the upper limit of normal (ULN) within 30 days  
> of study entry.
> Participants of both genders and all races are eligible.
> Must have received 1 prior combination chemotherapy regimen OR at  
> least 1 but no more than 2 prior single-agent regimens.
> History of anaphylaxis or other serious adverse reactions to vaccines.
> No prior therapy for high-grade glioma.
> ischemic or nonischemic cardiomyopathy.
> Patients with no prior chemotherapy for prostate cancer are excluded  
> from the phase II part of the study.
> Have received certain other drugs within 28 days before the study  
> drug will be taken, or think that they will be needed during the  
> study.
> Karnofsky 50-100% (adults).
> No unstable or severe concurrent medical condition that would  
> preclude study participation.
> Progressive disease after gemcitabine-based chemotherapy for  
> metastatic disease.
> No severe uncontrolled ventricular arrhythmias.
> No prior or concurrent cryotherapy.
> Capable of using the product and diaphragm properly.
> Ongoing AZT or ddI therapy of 6 months or longer duration.
> Localized metastases allowed provided the following are true:.
> B-cell lymphoproliferative disorders.
> No concurrent adrenal steroids (inhalant, topical, or optical  
> steroids allowed).
> No chronic cirrhosis.
> Concurrent short-term dexamethasone for chemotherapy-induced emesis  
> is allowed.
> Resistant or recurrent disease after combination chemotherapy with  
> at least one standard regimen.
> Cardiac ejection fraction within the institutional range of normal  
> as measured by echocardiogram.
> Have been immunized against smallpox.
> Pleural effusion.
> Patients must weight at least 40 kg (88 lbs.).
> Histologically and clinically confirmed pleural mesothelioma.
> Gleason score and PSA known.
> Have severe low blood count (anemia).
> SGOT no greater than 1.5 times normal.
> Adult dose of nevirapine, amprenavir, abacavir, lopinavir/ritonavir,  
> or off-label dosing of indinavir/ritonavir for at least 1 week  
> before PK sampling.
> No contraindications to MRI or CT scan (e.g., intracranial vascular  
> clips).
> Treatment with any medications that may cause lupus-like symptoms  
> within 4 weeks of baseline visit (e.g. procainamide, hydralazine).
> Basaloid carcinoma.
> Immunosuppressive or cytotoxic therapy.
> Stage IIIA (T1 or T2, N2) or IIIB disease not amenable to resection  
> or surgery.
> Are able to understand the study and pass a test showing they  
> understand it, and give written informed consent.
> No grade 2 or greater atrioventricular block.
> No prior radiotherapy to more than 15% of bone marrow.
> No secondary lymphoma after prior chemotherapy or radiotherapy for  
> other malignancies.
> Evaluate recurrent abdominal pain;.
> Infectious mononucleosis caused by cytomegalovirus (CMV) or Epstein- 
> Barr virus (EBV).
> No co-existent endocrine conditions.
> No prior or planned radical prostate surgery.
> Hematological function normal.
> Fertile patients must use effective contraception during and for 2  
> months following study.
> No hypersensitivity to any of the study drugs or their ingredients.
> Willing to limit sun exposure on day of PUVA therapy.
> Progressed while on or after treatment on platinum-based regimen.
> No severe hepatic dysfunction.
> Histologically confirmed myeloid metaplasia with myelofibrosis (MMM).
> Progressive disease after at least 1 standard chemotherapy or  
> chemoimmunotherapy regimen (e.g., dacarbazine or cisplatin  
> monotherapy).
> Alkaline phosphatase less than 4 times ULN.
> No history of cancer of the endometrium, vagina, or cervix.
> Progressed or recurred after 1, and only 1, prior cisplatin- or  
> carboplatin-containing systemic regimen for metastatic disease.
> Meets criteria for bipolar disorder, schizophrenia, bulimia/ 
> anorexia, dementia, major depression.
> No inability to comply with study and follow-up procedures.
> Children < 44 months old.
> Benzodiazepines within 14 days prior to study entry.
> Predicted postoperative FEV_1 greater than 1 by spirometry.
> Any other experimental therapy within 3 months of study entry.
> ALS.
> HIV infection. -Antecedent malignancy, whose prognosis is poor (<90%  
> probability of surviving for 5 yrs.).
> Absolute CD4 count of 200 cells/mm3 or greater.
> Have completed at least 60 weeks of treatment on ACTG 328.
> Identical for 1 HLA haplotype and mismatched at the HLA-A, -B, -C,  
> or DRB1 loci of the unshared haplotype.
> Disease progression while receiving an irinotecan-containing regimen  
> for metastatic colorectal cancer OR.
> T4 tumor based on malignant pleural effusion.
> Histologically confirmed previously untreated ovarian epithelial  
> carcinoma, peritoneal carcinoma, or fallopian tube carcinoma.
> At least 24 hours since prior transfusion.
> AST less than 2 times ULN.
> No prior oxaliplatin or irinotecan.
> Refractory to hormonal therapy.
> No prior endocrine therapy for breast cancer.
> Prior sentinel node biopsy or axillary node dissection allowed  
> provided nodes are pathologically negative.
> Acute cerebral trauma.
> Endocrine therapy: No prior hormonal therapy for prostate cancer.
> The subject is a known or suspected drug abuser.
> Cytokine inhibitors.
> No concurrent enrollment in investigational anticancer drug trials  
> that exclude the use of other investigational agents.
> Serum antibody to HTLV-III/LAV with or without viremia.
> On other immune-based therapy (e.g., interleukin-2, alpha  
> interferon, immunoglobulin, thalidomide) within 30 days prior to  
> study entry.
> Clinically significant gastrointestinal symptoms including  
> persistent nausea or abdominal pain.
> Have kidney disease or insufficiency.
> Bone marrow must not show evidence of other conditions associated  
> with myelofibrosis, including the following:.
> No concurrent antiretroviral therapy (HAART) for HIV positive  
> patients.
> Right ventricular enlargement.
> No prior radiotherapy to more than 25% of the total skeleton.
> No abnormal slit-lamp examination using a vital dye (e.g.,  
> fluorescein or Bengal-Rose).
> Non-Hodgkin's lymphoma or multiple myeloma; Autologous stem cells.
> WBC greater than 4,000/mm^3.
> Histologically proven pure germinoma.
> Patients who are iatrogenically immune-suppressed following organ  
> transplantation.
> Patients with unresolved bowel obstruction.
> Renal cancer.
> More than 4 weeks since prior soy products.
> End stage renal disease or receiving hemodialysis treatment.
> More than 14 days since prior investigational agents.
> Are taking certain medications such as ribavirin, hydroxyurea, and  
> ganciclovir.
> No prior lonafarnib.
> Registered to protocol MSKCC-9040 OR.
> Fertile patients must use effective double-barrier contraception  
> during and for 4 weeks after study.
> Can be followed at a participating Pediatric AIDS Clinical Trials  
> Unit (PACTU) for the entire study.
> Must have received 1 prior cytotoxic therapy regimen.
> Have a history of malignancy, except squamous or basal skin cancer.
> If significant clinical hearing loss already present, must accept  
> risk of further hearing loss.
> Increased blast cells (at least 5%) in peripheral blood or bone  
> marrow OR.
> No concurrent ganciclovir or foscarnet for previous CMV reactivation/ 
> infection.
> Histologically confirmed adenocarcinoma of the prostate previously  
> treated with androgen suppression.
> Suitable for nephrectomy.
> CALGB 0-1.
> Urine drug screen positive for a drug of abuse.
> Ability to communicate in English.
> Haemophilus B Conjugate vaccine.
> Age 18 to 50 with ALL in CR2 or greater and ineligible for  
> conventional allogeneic transplantation based on general medical  
> condition.
> Diagnosis of metastatic breast cancer.
> No aspirin (100 mg/day) within 1 week prior to surgery.
> No CNS lymphoma, AIDS-related lymphoma, or chronic lymphocytic  
> leukemia.
> Must have an initial diagnostic specimen that is CD20+.
> At least six months of prior cumulative ZDV therapy.
> No other malignancies within the past 5 years except curatively  
> treated malignancies with low risk of recurrence.
> Current acupressure, or Qi Gong, or acupuncture.
> Subcutaneous panniculitis-like PTCL.
> Current uncontrolled hypertension with systolic blood pressure in  
> excess of 200 mm Hg or diastolic blood pressure in excess of 115 mm  
> Hg.
> Have a diagnosis of other respiratory viruses (influenza, RSV, etc.).
> No standard therapy available that is potentially curative or  
> definitely capable of extending life expectancy.
> At least 6 Raynaud's attacks per week.
> Available tissue for central review.
> Willing and able to comply with the study procedures and visit  
> schedules.
> No concurrent administration of the following drugs:.
> Presence of fatigue with usual fatigue severity at least 3 on the  
> 0-10 numerical scale of the Brief Fatigue Inventory within the past  
> 14 days.
> Meets at least 1 other diagnostic criteria for NF1.
> Must be a resident of the Washington DC area.
> No concurrent prophylactic colony-stimulating factors for  
> myelosuppression.
> No prior HIV medications.
> Have an HIV-1 RNA of at least 5,000 copies/ml.
> Recent chest x-ray (within 24 hours) showing at least unilateral  
> infiltrations.
> Suboptimally debulked stage III or suboptimally or optimally  
> debulked stage IV.
> Isoniazid, if no alternative therapy is available.
> Life expectancy: No imminent demise.
> History of drug-induced neutropenia.
> No concurrent radiotherapy to greater than 10% of total liver, lung,  
> or bone marrow.
> Other anticytomegalovirus (CMV) therapy, particularly systemic  
> ganciclovir, foscarnet, or CMV hyperimmune globulin.
> Lomotil, Imodium, or deodorized opium tincture in a standardized  
> regimen for diarrhea.
> More than 7 days since prior fine needle aspirations or core biopsies.
> Have a drug allergy or other allergy which might cause a problem  
> during the study.
> No positive supraclavicular or scalene lymph nodes with disease  
> extending up into the cervical region OR.
> No concurrent chronic systemic steroids.
> No severe renal dysfunction defined as serum creatinine >1.6 mg/dL.
> Refractory to initial therapy OR recurrent following 1 induction  
> therapy regimen with or without consolidation therapy and/or bone  
> marrow transplantation.
> FEV_1 at least 1 L or 35% of predicted.
> Rhabdomyosarcoma (e.g., alveolar, embryonal, or pleomorphic).
> More than 4 months since prior definitive therapy (surgery or  
> radiotherapy) for brain metastases and must not have evidence of  
> disease on brain CT scan or MRI.
> If the patient does not know his/her vaccine history, it should be  
> presumed that he/she was vaccinated.
> Patients with symptomatic CNS metastases or leptomeningeal  
> involvement.
> No contralateral hilar disease or an exudative, bloody, or  
> cytologically malignant effusion.
> Previous participation in this trial.
> No concurrent intrathecal therapy during the first course of  
> decitabine.
> Any antiretroviral drug except zidovudine (AZT).
> Thrombocytopenia. Patients with the following prior conditions are  
> excluded:.
> Obtained no benefit from prior standard or salvage therapy.
> Significant negative symptoms with few positive symptoms (e.g.  
> hallucinations, delusions) and no evidence of major depression.
> Impaired renal function (serum creatinine > 2.0) and hepatic  
> function (bilirubin more than 2.0 x and transaminase more than 4.0 x  
> of the upper normal limit).
> No significant atelectasis (i.e., atelectasis of an entire lung).
> Adequate psychological support available.
> Not a candidate for stem cell transplantation or refuses one.
> No significant cardiac abnormalities by echocardiogram.
> PSA progression.
> Treatment with opiates within the last six months.
> Subjects must be considered reliable.
> Active malignancy other than Kaposi's sarcoma.
> Acceptable neurological and neuropsychological impairment scores.
> No active pancreatic disease.
> No residual tumor within 10 mm of optic chiasm.
> History of alcohol or drug abuse within the past 6 months.
> are planning to become pregnant.
> HAART regimen of two NRTIs and at least one PI (not nelfinavir).
> Have a gastrointestinal disorder that makes it difficult for  
> patients to absorb food or to take medications by mouth.
> Lycopene.
> No prior radiotherapy for rectal cancer.
> No lymphoma therapy for 3 weeks prior to Study Day 1.
> No more than one prior systemic chemotherapy regimen.
> No other concurrent standard or investigational chemotherapy.
> Have problems with their pregnancy and/or are expecting more than 1  
> baby.
> No prior or concurrent alcohol abuse or drug dependence.
> Primary refractory or relapsed (within the past year) disease.
> Patients who relapsed after autologous or allogeneic bone marrow or  
> peripheral blood stem cell transplantation are not eligible.
> Stable weight (+/- 2 kg) by 28 days prior to study entry.
> No medical or psychiatric condition that would preclude compliance.
> Be able to have a central venous like access maintained throughout  
> the study.
> Positive supraclavicular or scalene lymph nodes must not have  
> disease extending up into the cervical region.
> At least 6 weeks since prior chemotherapy and recovered.
> No severe pulmonary disease/illness.
> Any finding of tuberculosis, elevated ALT or AST, low hemoglobin  
> levels, low WBC and platelet count, high levels of serum creatinine.
> Immunoglobulins or vaccines within the past 3 months.
> Has taken an investigational drug or the medication Felbatol within  
> the previous 30 days.
> Absence of acute opportunistic infection at time of entry.
> Concurrent bisphosphonates (e.g., pamidronate) allowed if initiated  
> before study begins.
> Other curatively treated cancer and disease free for at least 10  
> years.
> Female patients who are not pregnant or lactating.
> Hepatic: No chronic or acute hepatic disorder.
> Stratum 3 (stages III or IV):.
> No history of allergic or other adverse reaction to gabapentin.
> No concurrent cytotoxic chemotherapy.
> Intractable diarrhea (>= 6 loose stools/day for >= 7 consecutive  
> days).
> Have taken at least 2 of the 3 licensed anti-HIV drug classes for at  
> least 3 months.
> Hospitalization within the past 14 days.
> No acute ischemia or active conduction system abnormalities by EKG.
> Resident of Zomba or Blantyre Districts, Malawi.
> Current diagnosis of community-acquired pneumonia.
> HLA genotypically identical donor available (under 75 years of age).
> Cerebral Kaposi's sarcoma.
> WBC greater than 1500/mm3.
> No prior peripheral neuropathy.
> At least 30 days since participation in another clinical study.
> No pre-existing grade 2 or greater motor or sensory peripheral  
> neuropathy except abnormalities due to cancer.
> No prior sirolimus.
> No uncontrolled medical illness.
> No other prior intracerebral chemotherapy.
> Are sensitive to acyclovir, Valtrex, famciclovir, or ganciclovir.
> Involvement in alcohol treatment other than provided by the study or  
> AA.
> Hematopoietic: No clinically significant hematologic disease No  
> hemodynamic instability.
> Have had a serious illness requiring systemic treatment and/or  
> hospitalization within 14 days prior to study entry.
> One tube of peripheral blood and one representative paraffin block  
> of tumor tissue must be available.
> No other concurrent participation in a protocol with pharmacological  
> intervention.
> No other major medical or psychiatric illness that would preclude  
> study compliance.
> Prior therapy with oxaliplatin.
> Not in first CR with Down syndrome.
> No history of second malignancy except adequately treated basal cell  
> skin cancer or carcinoma in situ of the cervix.
> No known peripheral vascular disease.
> No more than 1 cm linear dimension of contact between gadolinium- 
> enhancing tumor and a cerebral ventricle.
> No concurrent corticosteroids unless on stable dose of less than 20  
> mg/day of prednisone or equivalent and administered for reasons  
> unrelated to ovarian cancer.
> Willing and able to undergo serial bronchoscopic examinations.
> No leptomeningeal or brain metastases.
> Other myelosuppressive therapies which may be handled in the same  
> manner as AZT.
> No concurrent birth control pills or other hormonal therapy.
> Patients in the methotrexate arm must have started methotrexate  
> within 6 months of enrollment in the registry.
> No hip prosthesis.
> Failed standard or salvage therapy.
> Are allergic to any part of the chickenpox vaccine, including  
> neomycin.
> Active opportunistic infection requiring hospitalization or exclude  
> medication.
> Measurable disease outside of previously irradiated field unless  
> evidence of progression.
> No other concurrent serious, systemic disorder that would preclude  
> study.
> Other anti-retrovirals after consultation with the Syntex study  
> monitor.
> Acute opportunistic infection or other significant concurrent  
> illness that would preclude participation for the required 36 days.
> Concurrent enrollment on a HSCT protocol with the Experimental  
> Transplantation ; Immunology Branch (ETIB) at the NCI Center for  
> Clinical Research.
> Autism based on DSM-IV criteria.
> No primary germ cell tumor, small cell carcinoma, or lymphoma.
> Rising prostate-specific antigen AND radiographic evidence of  
> extraprostatic prostate cancer by bone scan, CT scan, prostascint  
> scan, or MRI.
> Prior cumulative doses of radiotherapy must not exceed the following:.
> Have used investigational research agents within 30 days prior to  
> enrollment.
> Known CNS metastases treated within 2 months of Day 1 or any  
> uncontrolled CNS metastases.
> Ineligible for a higher priority GOG protocol (if one exists).
> Prior adjuvant or neoadjuvant hormonal therapy of less than 8 months  
> duration allowed.
> Patients must have a Zubrod PS<2 (Appendix 6), Cr<2.0, direct  
> bilirubin <2, and transaminases SGPT <3x normal.
> Medical or psychiatric condition or occupational responsibilities  
> which could interfere with the study.
> 4 erupted maxillary incisors.
> Persistent, relapsed, or progressing malignancy.
> no treatment with systemic drugs for 1 month prior to the start of  
> the study.
> Ineligible for potentially curative surgical resection.
> Any disease or disorder listed in Patient Exclusion Co-existing  
> Conditions.
> Meets the criteria for alcohol dependence with comorbid bipolar  
> disorder.
> AST and/or ALT no greater than 4 times ULN.
> Rheumatoid arthritis or other autoimmune disease (serum ANA > 1:160).
> Presence of dementia, psychosis or other disorder of cognition that  
> impairs ability to participate in minimal contact intervention.
> Diagnosis of AIDS Dementia Complex (stage II or higher).

More information about the bioontology-support mailing list